Biotechnology

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

May 7, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor...

Read more

Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial

May 6, 2021 7:30 AM

First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced the start of the REBORN1© clinical trial. This trial is designed to evaluate...

Read more

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

May 6, 2021 7:00 AM

Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study...

Read more

American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

May 6, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / May 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerative Associates, LLC ("ARA") of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb...

Read more

Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro

May 6, 2021 1:00 AM

In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New York, in Addition to the Previously Reported Varia Ongoing Phase 2 Pilot Study of Ensovibep in Ambulatory Patients Now Expanding Into Second Cohort Two Global Phase 2 and 3 Clinical Studies of Ensovibep on Track for Initiation...

Read more

Wuhan General Group Secures Lab for Hemp and Mycelium Eco-Friendly Research & Development

May 5, 2021 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / May 5, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The hemp and mycelium eco-friendly R&D division of M2Bio Sciences, has secured a laboratory facility near its Woodstock office in Cape Town, South Africa. This will enable the...

Read more

Jubilant Radiopharma and Cylcomedica Europe Announce Their Partnership for the Distribution of RUBY-FILL(R) During the International Conference on Nuclear Cardiology

May 5, 2021 8:00 AM

YARDLEY, PA / ACCESSWIRE / May 5, 2021 / Jubilant Radiopharma, a business division of Jubilant Pharma Limited, and Cyclomedica Europe Ltd, a wholly owned subsidiary of Cyclopharm Limited (ASX:CYC), will announce their partnership at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC), taking place on May 9-11, 2021. Under the terms of the agreement, Cyclomedica was appointed the exclusive distributor of Jubilant...

Read more

RepliCel Announces Record Year in Patents Granted

May 5, 2021 6:00 AM

Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven...

Read more

Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

May 5, 2021 3:00 AM

This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™...

Read more

Apollo Endosurgery, Inc. Reports 29% Increase in First Quarter Revenue

May 4, 2021 4:01 PM

Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / May 4, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2021. Highlights Total revenue of $13.9 million, an increase of 29% from the first quarter of...

Read more

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

May 4, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note...

Read more

Havn Labs Jamaica Facility Now Fully Operational

May 4, 2021 8:00 AM

The Company has started production of its first grow with local partner Hypha Wellness VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it now has a fully operational mycology lab and production...

Read more

Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

May 4, 2021 7:30 AM

A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to...

Read more

Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline

May 4, 2021 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. "Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful...

Read more

Viewpoint Molecular Targeting(TM) Appoints Frank Morich, M.D., Ph.D. to its Board of Directors

May 3, 2021 10:00 AM

- Dr. Morich is an industry leader with over 35 years of experience in biopharmaceuticals with focus in commercialization, R&D and product development - - Previously served as Chief Commercial Officer of Takeda Pharmaceutical Company, Chief Executive Officer of Takeda Pharmaceutical International, Chief Executive Officer of NOXXON Pharma AG, Chief Executive Officer of Innogenetics N.V., and Head of Global Product Development of Bayer AG...

Read more

CO2 GRO Inc. Grants Stock Options

May 3, 2021 8:30 AM

TORONTO, ON / ACCESSWIRE / May 3, 2021 / CO2 GRO Inc. ("GROW" or the "Company") (TSXV: GROW, OTCQB: BLONF, Frankfurt: 4021) announces that the Board of Directors has approved the grant of 1,680,000 stock options (the "Options") to participants of the Company's stock option plan (the "Plan"). The Options are exercisable into common shares of the Company at an exercise price of $0.32 per share over the next three years, all vesting over the...

Read more

Noetic Foundry Appoints Dr. Tim Piser as Chief Scientific Officer

May 3, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / May 3, 2021 / Noetic Foundry, an operating company building psychedelic biotechnology startups, is pleased to announce the appointment of Dr. Tim Piser as its Chief Scientific Officer. Dr. Piser has over 25 years of neuroscience drug discovery and development expertise at both large pharmaceutical and early-stage biotechnology companies. His career has been driven by the overarching desire to develop novel medicines...

Read more

MJ Biotech, Inc. Submits Final Designs for CBD Extraction Facility, and a Second Foundation for Further Expansion

May 3, 2021 7:35 AM

CHEYENNE, WY / ACCESSWIRE / May 3, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV) partner, Genesis Botanical Research (GBR), is pleased to report they have broken ground on a second foundation which will be used to store hemp biomass. Plans for the structure arrived at GBR corporate offices, and several contractors are currently placing bids for the erection of the structure. Upon completion of this process, plans will be submitted for official town...

Read more

Apollo Endosurgery Announces Appointments to Commercial Leadership Team

May 3, 2021 7:00 AM

Kirk Ellis to Serve as Vice President of US Sales Steve Bosrock to Serve as Vice President of Marketing & Medical Education AUSTIN, TX / ACCESSWIRE / May 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointments of Kirk Ellis as Vice President of US Sales and Steve Bosrock as Vice President of Marketing...

Read more

Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

May 3, 2021 6:30 AM

The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the Company has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft...

Read more